The anticoagulant drugs which are available currently — coumarins and heparins — are reasonably effective but are insufficiently specific and often inconvenient to manage. An improved understanding of the physiology of blood coagulation and its control mechanisms has led to the identification of target enzymes for novel, specific and potentially safer antithrombotics. These targets include the pivotal coagulation enzyme thrombin as well as other enzymes and co-factors within the tissue factor dependent coagulation pathway. In addition, analogues of physiological anticoagulants hold promise as therapeutic agents. It is likely that the range of drugs available for the management of thrombosis will expand over the next decade. There is the very real possibility of the introduction of orally active agents which may be used in fixed dosage regimens with no requirement for laboratory monitoring.
Greinacher A.Lepirudin for the treatment of heparin induced thrombocytopenia. Heparin-induced thrombocytopenia (ed. By T.E Warkentin and A Greinacher) New York: Marcel Dekker, 2004;
2.
397-436. 2. Hirsh J., Heddle N., Kelton JGTreatment of heparin induced thrombocytopenia: a critical review. Archiv Intern Med2004;164:361-9.
3.
Warkentin TEBivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Practice and Research. Clin Haematol2004;17:105-25.
4.
Keeling DM, Davidson S., Watson HGThe management of heparin induced thrombocytopenia. Brit J Haematol2006;133:259-69.
5.
Greinacher A. , Eichler P., Lubenow R. et al. Heparin induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective studies to assess the value of parenteral treatment with lepirudin and its therapeutic APTT range. Blood2000;96:846-51.
6.
Lubenow R., Eichler P., Lietz T. et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies . Blood2004;104:3072-77.
7.
Greinacher A. , Lubenow R., Eichler P.Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia . Circulation2003;108:2062-5.
8.
Swan SK, Hursting MJThe pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic or renal dysfunction. Pharmacotherapy2000;20:318-29.
9.
Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin induced thrombocytopenia. Circulation2001;103:1838-43.
10.
Lewis BE, Wallis DE, Leya F. et al. Argatroban anticoagulation in patients with heparin induced thrombocytopenia . Arch Intern Med2003;163:1849-56.
11.
Sheth SB, DiCicco RA, Hursting MJ et al. Interpreting the International Normalised Ratio (INR) in individuals receiving argatroban and warfarin. Thrombos Haemostas2001;85:435-40.
12.
Lincoff AM, Bittl JA, Harrington RA for the REPLACE-2 Investigators.Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial. JAMA2003; 289:853-63.
13.
Rajagopal V. , Lincoff A., Michael MD et al. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart Journal2006;152:149-54.
14.
Eriksson UG, Johansson S., Attman PO et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clinical Pharmacokinetics2003;42:743-53.
15.
Heit JA, Colwell DW, Francis CW et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med2001;161:2215-21.
16.
Eriksson UG , Agnelli G., Cohen AT et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement . Thrombos Haemostas2003;89:288-96.
17.
Eriksson UG , Bergqvist D., Kalebo P. et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet2002;360:1441-7.
18.
Francis CW, Berkowitz SD, Comp PC et al. Comparison of ximelagatran with warfarin for prevention of venous thromboembolism after total knee replacement. N Engl J Med2003;349:1703-12.
19.
Executive Steering Committee on Behalf of the SPORTIF III investigators.Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet2003;362: 1691-8.
20.
Petersen P. , Grind M., Adler J. et al. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability and safety study. J Am Coll
21.
Cardiol2003;41:1445-51. 21. Eriksson H., Wahlander K., Gustafsson D. et al. A randomised controlled dose guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Thrombos Haemostas2003;1:41-7.
22.
Schulman S. , Wahlander K., Lundstrom T. et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran . N Engl J Med2003;349:1713-21.
23.
Eriksson BI , Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial . Thrombos Haemostas2005 ; 3:103-11.
24.
Bernard GR, Vincent JL, Laterrer PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001; 344:699-709.
25.
Abraham E., Laterre PF, Garg R. et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med2005; 353:1332-41.
26.
Green C., Dinnes J., Takeda A. et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess2005;9:1-126.
27.
Jo F., Adhikari NK, Meade MODrotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?Critical Care2006;10:145.
28.
Kearon C., Comp P., Douketis J. et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement . Thrombos Haemostas2005:3:962-8.
29.
Yusuf S., Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med2006;354:1464-76.
30.
Koopman MM, Buller HRShort- and long-acting synthetic pentasaccharides. J Intern Med2003;254:335-42.
31.
Berkowitz SD , Marder VJ, Kosutic G., Baughman RAOral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. Thrombos Haemostas2003;1:1914-19.
32.
Alexander JH , Yang H., Becker RC et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. Thrombos Haemostas2005;3:439-47.
33.
Eriksson BI, Borris L., Dahl OE et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after
34.
total hip replacement. J Thromb Haemost2006 ;4:121-8. 34. Lee AY, Vlasuk GPRecombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Inter Med2003 ;254:313-21.
35.
Abraham E., Reinhart K., Svoboda P. et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomised, placebo-controlled, single-blind dose escalation study. Crit Care Med2001;29:2081-9.
36.
Abraham E., Reinhart K., Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomised controlled trial. JAMA2003;290:238-47.
37.
Jilma B., Marsik C., Mayr F. et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther2002;72:403-10.
38.
Bauer KANew anticoagulants: anti IIa vs anti Xa- is one better?Thromb Thrombolysis2006;21:67-72.
39.
Bates SM, Weitz JIStatus of new anticoagulants. Brit J Haematol2006;134:3-19.
40.
Li T., Change CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature2004;427:541-4.
41.
Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med2005; 352:2285-93.
42.
Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HRA C1173T in the VKORC1 gene determines coumarin sensitivity and bleeding risk . PloS Med2005;2:e312.
43.
Taube J., Halsall D., Baglin T.Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood2000;96:1816-19.
44.
Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA2002 ;287:1690-8.
